| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-86 |
Sentence |
denotes |
Efficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: |
| T2 |
87-133 |
Sentence |
denotes |
A Randomized Active-Controlled Clinical Trial. |
| T3 |
134-144 |
Sentence |
denotes |
Objective: |
| T4 |
145-242 |
Sentence |
denotes |
Zuojin pill (ZJP) is used as the classical prescription for a wide variety of digestive diseases. |
| T5 |
243-355 |
Sentence |
denotes |
However, there is a lack of direct evidence for its use in the treatment of chronic nonatrophic gastritis (CNG). |
| T6 |
356-439 |
Sentence |
denotes |
In particular, there is a lack of rigorous trials of randomized controlled designs. |
| T7 |
440-566 |
Sentence |
denotes |
In this study, a randomized active-controlled clinical trial was performed to verify the efficacy and safety of ZJP in detail. |
| T8 |
567-575 |
Sentence |
denotes |
Methods: |
| T9 |
576-660 |
Sentence |
denotes |
Patients with CNG were divided into the ZJP group and the Marzulene-S granule group. |
| T10 |
661-740 |
Sentence |
denotes |
Patients were enrolled from September 2019 to February 2021 (ChiCTR2000040549). |
| T11 |
741-818 |
Sentence |
denotes |
Endoscopy and histology scores were evaluated as the primary outcome measure. |
| T12 |
819-939 |
Sentence |
denotes |
The Helicobacter pylori positive rate and the disappearance rate of symptoms were also measured to reflect the outcomes. |
| T13 |
940-1008 |
Sentence |
denotes |
Finally, adverse events were also calculated as the index of safety. |
| T14 |
1009-1017 |
Sentence |
denotes |
Results: |
| T15 |
1018-1143 |
Sentence |
denotes |
A total of 68 eligible patients were enrolled in this trial and randomly divided into two groups with baseline comparability. |
| T16 |
1144-1284 |
Sentence |
denotes |
ZJP was able to improve the red plaques as well as bile reflux scores compared with Marzulene-S granule (P=0.043 and P=0.019, respectively). |
| T17 |
1285-1373 |
Sentence |
denotes |
Moreover, it also remarkably alleviated the active chronic inflammation score (P=0.043). |
| T18 |
1374-1465 |
Sentence |
denotes |
However, there was no difference between the Helicobacter pylori positivity rate (P=0.752). |
| T19 |
1466-1638 |
Sentence |
denotes |
The symptom scores of abdominal distension (P=0.004), belching (P=0.010), and loss of appetite (P=0.019) were alleviated by ZJP, but nausea and vomiting were not (P=0.616). |
| T20 |
1639-1703 |
Sentence |
denotes |
ZJP can also be considered safe with no obvious adverse effects. |
| T21 |
1704-1780 |
Sentence |
denotes |
Conclusion: ZJP might decrease mucosal injury and alleviate symptoms in CNG. |
| T22 |
1781-1901 |
Sentence |
denotes |
In addition, more large-scale clinical trials should be carried out to further confirm its clinical efficacy and safety. |
| T1 |
0-86 |
Sentence |
denotes |
Efficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: |
| T2 |
87-133 |
Sentence |
denotes |
A Randomized Active-Controlled Clinical Trial. |
| T3 |
134-144 |
Sentence |
denotes |
Objective: |
| T4 |
145-242 |
Sentence |
denotes |
Zuojin pill (ZJP) is used as the classical prescription for a wide variety of digestive diseases. |
| T5 |
243-355 |
Sentence |
denotes |
However, there is a lack of direct evidence for its use in the treatment of chronic nonatrophic gastritis (CNG). |
| T6 |
356-439 |
Sentence |
denotes |
In particular, there is a lack of rigorous trials of randomized controlled designs. |
| T7 |
440-566 |
Sentence |
denotes |
In this study, a randomized active-controlled clinical trial was performed to verify the efficacy and safety of ZJP in detail. |
| T8 |
567-575 |
Sentence |
denotes |
Methods: |
| T9 |
576-660 |
Sentence |
denotes |
Patients with CNG were divided into the ZJP group and the Marzulene-S granule group. |
| T10 |
661-740 |
Sentence |
denotes |
Patients were enrolled from September 2019 to February 2021 (ChiCTR2000040549). |
| T11 |
741-818 |
Sentence |
denotes |
Endoscopy and histology scores were evaluated as the primary outcome measure. |
| T12 |
819-939 |
Sentence |
denotes |
The Helicobacter pylori positive rate and the disappearance rate of symptoms were also measured to reflect the outcomes. |
| T13 |
940-1008 |
Sentence |
denotes |
Finally, adverse events were also calculated as the index of safety. |
| T14 |
1009-1017 |
Sentence |
denotes |
Results: |
| T15 |
1018-1143 |
Sentence |
denotes |
A total of 68 eligible patients were enrolled in this trial and randomly divided into two groups with baseline comparability. |
| T16 |
1144-1284 |
Sentence |
denotes |
ZJP was able to improve the red plaques as well as bile reflux scores compared with Marzulene-S granule (P=0.043 and P=0.019, respectively). |
| T17 |
1285-1373 |
Sentence |
denotes |
Moreover, it also remarkably alleviated the active chronic inflammation score (P=0.043). |
| T18 |
1374-1465 |
Sentence |
denotes |
However, there was no difference between the Helicobacter pylori positivity rate (P=0.752). |
| T19 |
1466-1638 |
Sentence |
denotes |
The symptom scores of abdominal distension (P=0.004), belching (P=0.010), and loss of appetite (P=0.019) were alleviated by ZJP, but nausea and vomiting were not (P=0.616). |
| T20 |
1639-1703 |
Sentence |
denotes |
ZJP can also be considered safe with no obvious adverse effects. |
| T21 |
1704-1780 |
Sentence |
denotes |
Conclusion: ZJP might decrease mucosal injury and alleviate symptoms in CNG. |
| T22 |
1781-1901 |
Sentence |
denotes |
In addition, more large-scale clinical trials should be carried out to further confirm its clinical efficacy and safety. |